These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26301067)

  • 21. Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?
    Härmark L; Raine J; Leufkens H; Edwards IR; Moretti U; Sarinic VM; Kant A
    Drug Saf; 2016 Oct; 39(10):883-90. PubMed ID: 27379887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
    Abou Taam M; Ferard C; Rocle P; Maison P
    Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
    Lane S; Lynn E; Shakir S
    BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk minimization activities of centrally authorized products in the EU: a descriptive study.
    Zomerdijk IM; Sayed-Tabatabaei FA; Trifirò G; Blackburn SC; Sturkenboom MC; Straus SM
    Drug Saf; 2012 Apr; 35(4):299-314. PubMed ID: 22339506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Risk communication efforts regarding drug safety in the US and EU, and Japan].
    Yamamoto M
    Yakugaku Zasshi; 2012; 132(5):533-48. PubMed ID: 22687688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media.
    Ghosh R; Lewis D
    Expert Opin Drug Saf; 2015; 14(12):1845-53. PubMed ID: 26436834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient Reporting in the EU: Analysis of EudraVigilance Data.
    Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
    Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
    Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An assessment of the hospital exemption landscape across European Member States: regulatory frameworks, use and impact.
    Hills A; Awigena-Cook J; Genenz K; Ostertag M; Butler S; Eggimann AV; Hubert A
    Cytotherapy; 2020 Dec; 22(12):772-779.e1. PubMed ID: 33046395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports.
    Jullian S; Jaskiewicz L; Pfannkuche HJ; Parker J; Lalande-Luesink I; Lewis DJ; Close P
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):971-9. PubMed ID: 26175055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers.
    Klein K; De Bruin ML; Broekmans AW; Stolk P
    BioDrugs; 2015 Dec; 29(6):373-9. PubMed ID: 26621793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention.
    Goedecke T; Ord K; Newbould V; Brosch S; Arlett P
    Drug Saf; 2016 Jun; 39(6):491-500. PubMed ID: 26940903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ.
    Borg JJ; Laslop A; Pani L; Maciulaitis R; Melchiorri D
    Sci Pharm; 2014; 82(3):541-54. PubMed ID: 25853067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view].
    Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
    Blake KV; Prilla S; Accadebled S; Guimier M; Biscaro M; Persson I; Arlett P; Blackburn S; Fitt H
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1021-9. PubMed ID: 22039593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.